Clinical trials: Oral Phase
Primary Insomnia
Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia
The purpose of this study is to evaluate the efficacy and safety of sublingual zolpidem presentation 5 mg in the induction of sleep in patients with primary insomnia.
- Trial name
- NCT01896336
- Testing
- Zolpidem Hemitartrate
- Where
- Brazil
- Volunteers
- 67 people
- Sponsor
- EMS
Healthy
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
Primary objective mass balance, excretion pathways and metabolism following a single oral dose of [14C]BI 1467335 given to healthy male subjects (a selected number of subjects will be treated with [14C]BI 1467335 after a…
- Trial name
- NCT03382509
- Testing
- [14C]BI 1467335, BI 1467335
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypogonadism
Oral Testosterone for the Treatment of Hypogonadism in Males
Low testosterone is a condition that occurs when the body is unable to produce sufficient quantities of testosterone. The medical name for low testosterone is hypogonadism. Hypogonadism can be caused by many factors.
- Trial name
- NCT02222558
- Testing
- TSX-002
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TesoRx Pharma, LLC
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers
The purpose of this study is to evaluate the relationship between plasma drug levels and receptor binding in brain using PET; and to evaluate safety and tolerability after a single administration of PF-05212365 in healthy…
- Trial name
- 3193A1-1103 (NCT01253655)
- Testing
- PF-05212365
- Where
- 3 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Metastatic Breast Cancer
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.
- Trial name
- NCT00265655
- Testing
- Satraplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Agennix
B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia
A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with relapse or refractory B cell malignant hematological…
- Trial name
- NCT03757000
- Testing
- YY-20394
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Healthy Volunteers
A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants
The purpose of this study is to evaluate the effect of CC-99677 coadministration on the pharmacokinetics (PK) of an oral contraceptive (OC).
- Trial name
- NCT04718636
- Testing
- Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Bacterial Infections
A Single Dose Study of Debio 1450 in Healthy Subjects
The sponsor is trying to develop a medicine for infections that are not cured by regular antibiotics. They have an experimental drug called Debio 1450 that may work. They need about 48 healthy adults to volunteer for this study.
- Trial name
- NCT02162199
- Testing
- Debio 1450
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Debiopharm International SA
Healthy Volunteer
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.
- Trial name
- NCT07425899
- Testing
- ABBV-722, Upadacitinib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AbbVie
Crohn's Disease
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
This is a randomized, double-blind, placebo-controlled, multicenter, and proof of concept study with a parallel group design to evaluate the safety and efficacy of oral Trichuris Suis Ova (TSO) suspension, as compared to placebo…
- Trial name
- TRUST-I (NCT01576471)
- Testing
- Trichuris suis ova (TSO)
- Where
- 73 sites in United States
- Volunteers
- 250 people
- Sponsor
- Coronado Biosciences, Inc.
Age-related Macular Degeneration
QA102 Phase 1 Study in Healthy Young and Older Adult Subjects
This will be a double masked, randomized, placebo controlled, single and multiple oral dose study conducted in 3 parts. The safety and tolerability of single and multiple ascending oral doses of QA102 in healthy young and older…
- Trial name
- NCT04894071
- Testing
- QA102
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Smilebiotek Zhuhai Limited
Cystic Fibrosis
PTC124 for Cystic Fibrosis
In some patients with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein.
- Trial name
- NCT00234663
- Testing
- PTC124
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- PTC Therapeutics
Pulmonary Hypertension Associated With Sickle Cell Disease
Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)
This is a multicenter, randomized (2:1; oral treprostinil:placebo), double-blind, placebo-controlled event-driven (time to pulmonary hypertension [PH] clinical worsening) study in subjects with PH associated with sickle cell…
- Trial name
- NCT03055234
- Testing
- Oral Treprostinil
- Sponsor
- United Therapeutics
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed.
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01926587
- Testing
- oral rigosertib, Azacitidine
- Where
- 13 sites in United States, France
- Volunteers
- 45 people
- Sponsor
- Traws Pharma, Inc.
Breast Neoplasms, Neoplasm Metastasis
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment.
- Trial name
- NCT00083993
- Testing
- Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
- Where
- 129 sites in United States, Canada
- Volunteers
- 1,236 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy Volunteers
Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845
To demonstrate the safety, pharmacokinetics and pharmacodynamics of drug candidate.
- Trial name
- NCT00856258
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mast Cell Activation Syndrome
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.
- Trial name
- NCT05449444
- Testing
- Masitinib 4.5 mg/kg/day, Best supportive care, Masitinib 6.0 mg/kg/day
- Where
- 4 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- AB Science
Carcinoma, Non-Small-Cell Lung
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment
- Trial name
- NCT02182232
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Venous Thrombosis, Deep Vein Thrombosis
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for…
- Trial name
- NCT00839163
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Enoxaparin/Vitamin K-Antagonist
- Where
- 110 sites in Australia, Austria and 17 more
- Volunteers
- 613 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.